Tabula Rasa HealthCare downgraded by Baird with a new price target
$TRHC
Business Services
Consumer Discretionary
Baird downgraded Tabula Rasa HealthCare from Outperform to Neutral and set a new price target of $11.00 from $24.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/10/2023 | $7.00 → $10.00 | Market Perform → Outperform | SVB Securities |
| 3/2/2022 | $30.00 → $15.00 | Buy | Benchmark |
| 2/28/2022 | $23.00 → $11.00 | Market Perform | SVB Leerink |
| 2/1/2022 | $24.00 → $11.00 | Outperform → Neutral | Robert W. Baird |
| 2/1/2022 | $24.00 → $11.00 | Outperform → Neutral | Baird |
| 12/2/2021 | $13.00 | Hold | Jefferies |
| 11/8/2021 | $70.00 → $23.00 | Outperform | RBC Capital |
| 11/8/2021 | $40.00 → $23.00 | Market Perform | SVB Leerink |
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)